U.S.-based multistate cannabis operator Curaleaf Holdings on Tuesday escalated its pursuit of Aurora Cannabis by formally launching a hostile takeover bid that values Aurora at US$4.00 per share. The offer, conveyed directly to Aurora shareholders after private outreach failed to produce negotiated engagement, has already prompted the Aurora board to set up a special committee to review the proposal.
Terms and timeline
The bid comprises 0.3463 of a Curaleaf subordinate voting share plus US$0.75 in cash for each Aurora common share and is structured as a tender offer that will remain open until Dec. 1, 2026. Curaleaf said the proposal carries no financing or due diligence conditions and is subject only to customary regulatory approvals.
| Offer element | Detail |
|---|---|
| Implied value per Aurora share | US$4.00 |
| Curaleaf share component | 0.3463 Curaleaf subordinate voting share |
| Cash component | US$0.75 per Aurora share |
| Tender offer deadline | Dec. 1, 2026 |
Curaleaf rationale and past engagement
Curaleaf framed the move as an attempt to create a larger, more diversified global platform and told investors the price represents a significant premium to Aurora’s unaffected trading level. The company said it made multiple private approaches to Aurora’s board seeking to negotiate before resorting to a public offer.
“Today, we are putting this proposal directly in the hands of Aurora shareholders,”
Curaleaf Chairman and CEO Boris Jordan wrote in the company statement accompanying the offer.
Financial context highlighted by Curaleaf
In its public pitch, Curaleaf pointed to mounting pressures on Aurora’s core business, including reduced Canadian medical cannabis reimbursement rates and the cancellation of German medical cannabis reimbursement. The U.S. suitor also flagged consecutive quarters of underperformance and cited roughly CA$4.65 billion in impairments Aurora recorded from fiscal 2020 through fiscal 2026.
- Curaleaf says the offer implies a 45 per cent premium to Aurora’s unaffected share price.
- The proposal is capped and not subject to financing or due diligence conditions, per Curaleaf.
- Aurora has formed a special committee to consider the approach.
Aurora’s immediate response and local implications
Aurora publicly pushed back ahead of the tender offer, saying the company had recently corresponded with Curaleaf’s CEO and remains focused on executing its business plan in the short to medium term, while not ruling out further dialogue. After the formal offer arrived, Aurora’s board established a special committee to review the bid.
For Aurora residents, the outcome could have direct effects on local employment and the corporate presence in the city. Aurora Cannabis is a prominent local company with operations and staff whose futures are tied to strategic decisions and any possible change in ownership. A takeover by a U.S. MSO would also touch on cross-border regulatory and market dynamics that have weighed on the sector for years.
Curaleaf’s public filing characterises potential benefits to Aurora shareholders as including scale, diversification and access to the U.S. market, with the suitor pointing to potential cost synergies. Whether Aurora shareholders, including local investors, view the offer as compelling will be a central question as the tender remains open into December.
As the calendar moves toward the tender deadline, Aurora’s special committee and shareholders will weigh Curaleaf’s valuation and assertions against the company’s own recovery plan and any alternative strategic options. The development adds fresh uncertainty for staff, suppliers and municipal observers in Aurora who watch the company’s fortunes closely.
WE NEWS will continue to monitor filings and statements from both companies and report further developments affecting Aurora and the wider Ontario cannabis sector.
